CURRICULUM VITAE 2005

Transcription

1 CURRICULUM VITAE 2005 Last Name : GLEHEN Fist Name: Olivier Current Address Department of Surgical Oncology University Hospital of LYON-SUD Pierre Bénite, France olivier.glehen@chu-lyon.fr Date of birth : 29 décembre 1969 in Lyon (69003) France. Nationality : French. Married, 3 daughters. Hospital Activity : SENIOR GENERAL SURGEON (MD, PhD) in the Department of Surgical Oncology (University Hospital of Lyon Sud Pr Gilly) Surgical Training RESIDENT OF LYON UNIVERSATORY HOSPITAL : MD of Lyon-I University : 1998 GENERAL and DIGESTIVE SURGEON of Lyon-I University, 1997 ASSISTANT CHEF DE CLINIQUE (FELLOWSHIP) OF LYON UNIVERSITY HOSPITAL DEPARTMENT OF VASCULAR SURGERY (CHEVALIER MD, PHD) at Edouard Herriot Hospital DEPARTMENT OF GENERAL AND THORACIC SURGERY (VIGNAL MD, PHD/ GILLY MD, PHD) : at University Hospital Lyon-sud RESEARCH FELLOW Surgical Oncology (Washington Hospital Center, Dr Sugarbaker): INTERNATIONAL POST-GRADUATE TRAINING Surgical department of Mount Sinai Medical Center in New-York (J.Bauer, MD, PhD) : May- June 2000 Academic Training PhD IN GENERAL SURGERY of Lyon-I University : 2004 Scientific Society And Research Associations Member of l International Society on Clinical Hyperthermia (Indianapolis, USA) since 2000, of Société de Chirurgie de Lyon since 2001, of International Association of Surgeons & Gastroenterologists since 2000, of International Society of Intraoperative Radiation Therapy since 1999 (Mayo Clinic, Rochester)

2 Academic Activity Director of «Loco-regional treatment of peritoneal carcinomatosis» Laboratory, EA 3738 Claude Bernard Lyon-I University. Professor in Lyon-Sud Faculty: General Surgery Congress Participation (Invitation : *) Académie Nationale de Chirurgie, Paris, Novembre 2000 et Janvier 2002*, Surgical Research Conference of Mount Sinai, New York, Mai.2000*, Journées Chirurgicales de Colombes, Paris, Janvier 2001.* Journées Chirurgicales de Grenoble, Grenoble, Janvier 2001.* XXIV International Congress on Clinical Hyperthermia, Rome, Septembre 2001.*Meeting on «Multimodal Therapy of the locally advanced rectal cancer», Munich, Octobre 2001.* 7ème Journée de Cancérologie Jean Papillon, «Les cancers de la sphère digestive haute», Lyon, Juin 2003.* Surgical Oncology Conference, Washington Hospital Center, Avril 2003.* 15 th International Congress on anti-cancer treatment, Paris, Fevrier 2004.* 11ème Conférence Internationale d Oncologie Digestive, Arcachon, Octobre 2004.* 4th International Workshop on Peritoneal Surface Malignancy, Madrid, Decembre 2004* Journée Scientifique du Collège Lyonnais de Colo-Proctologie, Lyon, Septembre 2004.* Congrès de Association Rhône-Alpes de Formation Continue en HépatoGastroentérologie, Lyon, Février 2005.* VIIème journée lyonnaise de cancérologie digestive, Lyon, Mars 2004.* 29 th National Congress of the Italian Society of Surgical Oncology, Rome, Avril 2005.* Journées de Chirurgie Bourgogne-Rhône-Alpes, Dijon, (Merit award). XXIII Meeting of the International Clinical Hyperthermia Society, Lyon, Juin nd International Symposium Sphincter saving treatment in Rectal Cancer, Lyon, th World Congress of the International Association of Surgeons and Gastroenterologists, Crète, Novembre ASCO Gastrointestinal Cancers Symposium, San Fransisco, Janvier 2004 (Merit Award Winning Abstract). Président du XXIII Meeting of the International Clinical Hyperthermia Society, LYON, Juin Publications in national journals (n = 16) and in international journals (n = 41) Principal 1. Digestive surgery combined with peritonectomy procedures and intraperitoneal chemo-hyperthermia in abdominal cancers with peritoneal carcinomatosis : a phase II study. GLEHEN O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN. J Clin Oncol, 2003, 21, Intraperitoneal chemohyperthermia using a closed technique and cytoreductive surgery for the treatment of peritoneal carcinomatosis : morbidity and mortality analysis of 216 consecutive procedures. GLEHEN O, Osinsky D, Cotte E, Beaujard AC, Benoit M, Freyer G, Francois Y, Peyrat P, Vignal J, Gilly FN. Ann Surg Oncol 2003; 10(8): Treatment of peritoneal carcinomatosis arising from gastric cancer by surgery and intraperitoneal chemohyperthermia. GLEHEN O, Schreiber V, Cotte E, Beaujard AC, Osinsky D, Freyer G, Francois Y, Vignal J, Gilly FN. Arch Surg 2004;139: Intraperitoneal chemohyperthermia and cytoreductive surgery in patients with peritoneal carcinomatosis from colorectal origin. GLEHEN O, Cotte E, Schreiber V, Beaujard AC, Osinsky D, Freyer G, Francois Y, Vignal J, Gilly FN. Br J Surg 2004;91: Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. GLEHEN O, Mohamed F, Sugarbaker PH. Ann Surg 2004;240: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal carcinomatosis: A multi-institutional registry of 506 patients. GLEHEN O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA,

3 Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P. J Clin Oncol 2004;22: I35- Hyperthermic intraperitoneal melphalan: pharmacokinetics, metabolism, and tissue distribution in a rat model. GLEHEN O, Stuart OA, Mohamed F, Yoo D, Sugarbaker PH. Cancer Chemother Pharmacol 2004;54: Digestive peritoneal carcinomatosis : new management by cytoreductive surgery and intraperitoneal chemohyperthermia. GLEHEN O, Mohamed F, Gilly FN. Lancet Oncol 2004;5:219-28

4 SCIENTIFIC WORK My scientific work is focused on the loco-regional treatment of peritoneal carcinomatosis (from colorectal, gastric and ovarian origin as well as pseudomyxoma peritonei and peritoneal mesothelioma) including the techniques of peritonectomy and intraperitoneal chemohyperthermia (IPCH). More than 400 treatment combining cytoreductive surgery and IPCH have been performed in our department since In Lyon-Sud, we are currently working on the intraperitoneal administration of new chemotherapeutics agents such as melphalan for ovarian carcinomatosis and irinotécan for digestive carcinomatosis and we are especially studying pharmacokinetics of these two drugs. Two multicentric national phase II studies are undergoing. We are also working on preoperative assessment of carcinomatosis and on Pet-CT-scan findings for pseudomyxoma peritonei. In our laboratory, we are working on the treatment of non resectable carcinomatosis by the development of vaccine against tumor. I will present in Messina the international experience in colorectal carcinomatosis treated with cytoreductive surgery combined with perioperative intraperitoneal chemotherapy and I am joining the abstract.

5 REPORT Treatment of peritoneal carcinomatosis from colorectal origin with cytoreductive surgery combined with perioperative intraperitoneal chemohyperthermia. Glehen O, Gilly FN, Cotte E, and the colorectal carcinomatosis study group. Surgical oncology Department, University Hospital Lyon Sud, France The three principal studies dedicated to the natural history of peritoneal carcinomatosis (PC) from colorectal cancer consistently showed median survival ranging between 6 and 8 months. This survival is probably underestimated since the development of new systemic chemotherapeutic agents. But in 2005, the only approach which suggests improved survival is the combination of cytoreductive surgery with perioperative intraperitoneal chemotherapy. A retrospective multicentric study was performed to evaluate the international experience with this combined treatment and to identify the principal prognostic indicators. All patients had cytoreductive surgery and perioperative intraperitoneal chemotherapy (intraperitoneal chemohyperthermia and/or immediate postoperative intraperitoneal chemotherapy). This study included 506 patients from 28 institutions. With a median follow-up of 53 months, the morbidity and mortality rates were 22.9 and 4%, respectively and the overall median survival was 19,2 months. Patients in whom cytoreductive surgery was complete had a median survival of 32.4 months compared to 8.4 months for patients in whom complete cytoreductive surgery was not possible (p<.001). Positive independent prognostic indicators by multivariate analysis were complete cytoreduction, treatment by a second procedure, limited extent of PC, age less than 65, and use of adjuvant chemotherapy. The use of neoadjuvant chemotherapy, lymph node involvement, presence of liver metastasis and poor histological differentiation were negative independent prognostic indicators. These results following those of the randomized study from the Netherland Cancer Institute (J Clin Oncol 2004) authorize some conclusions: the therapeutic approach combining cytoreductive surgery with perioperative intraperitoneal chemotherapy may achieve long-term survival in a selected group of patients with PC from colorectal origin with acceptable morbidity and mortality. The complete cytoreductive surgery is the most important prognostic indicator.